News August 2004 Issue

In The News: 08/04

Alendronate: Staying Power For Osteoporosis Patients

The osteoporosis drug alendronate (Fosamax), a non-hormonal medication which slows bone loss and increases bone density by promoting bone mineralization, continues to help prevent bone loss years after patients stop taking it. A 10-year study among 247 post-menopausal women found that bone mineral density in the spine increased nearly 14 percent among those who took 10mg of alendronate daily for 10 years. Patients who took 20mg of the drug daily…

To continue reading this article you must be a paid subscriber.

Subscribe to Arthritis Advisor

Arthritis Advisor is the first magazine published by one one of the world's leading orthopaedic hospitals specifically for people with arthritis.

Subscriber Log In

Forgot your password? Click Here.

Already subscribe but haven't registered for all the benefits of the website? Click here.